| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | lapatinib | CCLE | pan-cancer | AAC | -0.28 | 1e-08 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | -0.21 | 3e-05 |
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | -0.25 | 7e-05 |
| mRNA | lapatinib | gCSI | pan-cancer | AAC | -0.23 | 0.0001 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | -0.13 | 0.0002 |
| mRNA | TKI258 | CCLE | pan-cancer | AAC | 0.19 | 0.0002 |
| mRNA | 5-FU | CTRPv2 | pan-cancer | AAC | -0.13 | 0.0003 |
| mRNA | lapatinib | CTRPv2 | pan-cancer | AAC | -0.13 | 0.0006 |
| mRNA | Erlotinib | CTRPv2 | pan-cancer | AAC | -0.12 | 0.0009 |
| mRNA | lapatinib | GDSC1000 | pan-cancer | AAC | -0.16 | 0.002 |